Meningococcal vaccine group B conjugate - Sanofi-Aventis

Drug Profile

Meningococcal vaccine group B conjugate - Sanofi-Aventis

Alternative Names: Group B meningococcal polysaccharide conjugate vaccine - sanofi pasteur

Latest Information Update: 15 Apr 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator sanofi pasteur
  • Class Meningococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Meningococcal group B infections

Most Recent Events

  • 15 Apr 2008 Discontinued - Phase-I for Meningococcal group B infections in France (IM)
  • 26 May 2006 This vaccine is still in active development
  • 21 Jan 2005 Aventis Pasteur is now called sanofi pasteur
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top